Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients follwing 4 weeks of treatment with bisoprolol and metoprolol: A randomized multicentre double-blind study (BISOMET)

Aim: To assess the effects of chronic evening oral administration of bromazepam alone or in combination with propranolol on ambulatory blood pressure (BP) and heart rate (HR) in mild hypertensive subjects. Methods: Thirty-seven mild hypertensive patients after a 2-week placebo period were randomized to bromazepam 3 mg, propranolol 40 mg, bromazepam 3 mg plus propranolol 40 mg or placebo for 2 weeks according to a double-blind, double dummy, cross-over design. After each treatment period, 24-h BP and HR ambulatory monitoring was performed by using a non-invasive device. Results: Ambulatory monitoring showed that during night-time SBP and DBP values were unaffected by bromazepam as compared to placebo, whereas SBP was significantly reduced by propranolol both when taken alone and in combination with bromazepam. HR nocturnal values were significantly reduced by propranolol, whereas they were significantly increased by bromazepan both when taken alone (+11.5%, p < 0.05 vs. placebo) and in combination with propranolol (+12.8%, p < 0.05 vs. propranolol). No significant difference in day-time values of SBP, DBP and HR was observed among the 4 treatment groups. Conclusions: In mild hypertensive patients, evening consumption of bromazepam for a 2-week period did not affect BP, while it increased nocturnal HR. Such an increase was observed both when bromazepam was taken alone and in combination with propranolol, which suggests that it depends on a bromazepam mediated decrease in vagal tone. Whatever the mechanism, the HR nocturnal increase might be of clinical relevance, due to the role of high HR as cardiovascular risk factor, particularly in already at risk hypertensive subjects.

Download Full-text

Effect of the Calcium Antagonist Benidipine Hydrochloride on 24-h Ambulatory Blood Pressure in Patients with Mild to Moderate Hypertension in a Double-Blind Study against Placebo

Arzneimittelforschung ◽

10.1055/s-0031-1300260 ◽

2011 ◽

Vol 50 (07) ◽

pp. 620-625

Author(s):

Osamu Nakajima ◽

Hisashi Akioka ◽

Mizuo Miyazaki

Keyword(s):

Blood Pressure ◽

Calcium Antagonist ◽

Ambulatory Blood Pressure ◽

Moderate Hypertension ◽

Blind Study ◽

Double Blind Study ◽

Double Blind

Download Full-text

Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial

European Heart Journal ◽

10.1093/eurheartj/ehy871 ◽

2019 ◽

Vol 40 (9) ◽

pp. 743-751 ◽

Cited By ~ 17

Author(s):

Michael Böhm ◽

Felix Mahfoud ◽

Raymond R Townsend ◽

David E Kandzari ◽

Stuart Pocock ◽

...

Keyword(s):

Heart Rate ◽

Renal Denervation ◽

Heart Rate Reduction ◽

Proof Of Concept ◽

Rate Reduction ◽

Hypertensive Patients

Download Full-text

Effectiveness of Oral Diclofenac in the Acute Treatment of Common Migraine Attacks: A Double-Blind Study Versus Placebo

Cephalalgia ◽

10.1046/j.1468-2982.1991.1102059.x ◽

1991 ◽

Vol 11 (2) ◽

pp. 59-63 ◽

Cited By ~ 25

Author(s):

Hélène Massiou ◽

Dominique Serrurier ◽

Odile Lasserre ◽

Marie-Germaine Bousser

Keyword(s):

Clinical Relevance ◽

Acute Treatment ◽

Migraine Without Aura ◽

International Headache Society ◽

Blind Study ◽

Drug Intake ◽

Double Blind Study ◽

Double Blind ◽

The One

In a multicentre double-blind cross-over trial, oral diclofenac at a dose of 50 mg to 100 mg was compared to placebo in the acute treatment of migraine attacks. A hundred and seven patients suffering from migraine without aura were included, and 91 were analysed for efficacy; they had to treat four successive attacks-two with diclofenac and two with placebo. Diclofenac was significantly more effective than placebo ( p < 0.05) on the main judgement parameter, which was the number of attacks aborted within 2 h of drug intake, as well as on the following secondary parameters: the necessity for an escape medication and the evaluation of global efficacy. Diclofenac was well tolerated. This trial demonstrates the efficacy of diclofenac in the acute treatment of migraine attacks. It confirms the good clinical relevance of the main judgement parameter chosen, which is the one recommended by the International Headache Society, but appears to be a severe one in terms of successes.

Download Full-text